Key Highlights
- MilliporeSigma to acquire Mirus Bio for $600 million.
- Enhances portfolio with Mirus Bio’s leading transfection reagents.
- Supports growing demand for viral vector-based gene therapies.
- Deal expected to close in Q3 of 2024.
Source: Business Wire
Notable Quotes
- “Viral vector-based cell and gene therapies have demonstrated their potential with more than 20 approvals over the last 10 years and will continue to advance, with a projected growth of 30 percent until 2028,” – Matthias Heinzel, Member of the Executive Board and CEO Life Science at Merck KGaA, Darmstadt, Germany
- “MilliporeSigma’s broad portfolio, scale, and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide,” – Dale Gordon, CEO at Mirus Bio
SoHC's Take
The acquisition of Mirus Bio by MilliporeSigma marks a significant expansion in the life science field, particularly in the development and commercialization of transfection reagents critical for viral vector-based gene therapies. This strategic move not only strengthens MilliporeSigma’s already comprehensive portfolio but also positions it to meet the increasing global demand for innovative gene therapy solutions. As the market for these therapies continues to grow, MilliporeSigma’s enhanced capabilities will likely play a crucial role in advancing medical science and improving patient outcomes worldwide. The deal, pending regulatory approval, is set to close in Q3 of 2024, indicating a promising future for both companies.
